High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a super(177)Lu...
High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a super(177)Lu-based CD22-specific radioimmunoconjugate and rituximab
About this item
Full title
Author / Creator
Journal title
Language
English
Formats
More information
Scope and Contents
Contents
Dual-targeted therapy has been shown to be a promising treatment option in recurrent and/or refractory B-cell non-Hodgkin's lymphoma (B-NHL). We generated radioimmunoconjugates (RICs) comprising either a novel humanized anti-CD22 monoclonal antibody, huRFB4, or rituximab, and the low-energy beta -emitter super(177)Lu. Both RICs were evaluated as si...
Alternative Titles
Full title
High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a super(177)Lu-based CD22-specific radioimmunoconjugate and rituximab
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1765977197
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1765977197
Other Identifiers
ISSN
1619-7070
E-ISSN
1619-7089
DOI
10.1007/s00259-015-3175-6
